CelluTarget · Multifocal Motor Neuropathy · Clinical Trials
Phase 2
Recruiting
NCT05686551

Tominersen (RG6042)

Sponsored by Roche / Genentech ↗
View on ClinicalTrials.gov ↗
Timeline
Study Dates
Start Date
January 2023
Est. Completion
December 2028
Enrollment Target
360 participants
Status
Recruiting
Study Design
Primary Endpoint
Change from baseline in composite Unified Huntington's Disease Rating Scale (cUHDRS) at lower, less-frequent dosing in younger patients with less disease burden
Registry
ClinicalTrials.gov Record
Registry ID
NCT05686551
Direct Link
clinicaltrials.gov/NCT05686551 ↗
Related Treatment
Treatment Being Studied
Tominersen (RG6042) →